ZA895546B - New solid porous unitary form comprising micro-particles and/or nano-particles,and its preparation - Google Patents

New solid porous unitary form comprising micro-particles and/or nano-particles,and its preparation

Info

Publication number
ZA895546B
ZA895546B ZA895546A ZA895546A ZA895546B ZA 895546 B ZA895546 B ZA 895546B ZA 895546 A ZA895546 A ZA 895546A ZA 895546 A ZA895546 A ZA 895546A ZA 895546 B ZA895546 B ZA 895546B
Authority
ZA
South Africa
Prior art keywords
particles
preparation
nano
micro
new solid
Prior art date
Application number
ZA895546A
Other languages
English (en)
Inventor
Frederic Courteille
Courteille Frederic
Anne Coutel
Coutel Anne
Guy Lebreton
Lebreton Guy
Michel Veillard
Veillard Michel
Original Assignee
Farmalyoc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalyoc filed Critical Farmalyoc
Publication of ZA895546B publication Critical patent/ZA895546B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Silicon Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Cosmetics (AREA)
  • Catalysts (AREA)
ZA895546A 1988-07-21 1989-07-20 New solid porous unitary form comprising micro-particles and/or nano-particles,and its preparation ZA895546B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8809864A FR2634376B1 (fr) 1988-07-21 1988-07-21 Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation

Publications (1)

Publication Number Publication Date
ZA895546B true ZA895546B (en) 1990-04-25

Family

ID=9368634

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA895546A ZA895546B (en) 1988-07-21 1989-07-20 New solid porous unitary form comprising micro-particles and/or nano-particles,and its preparation

Country Status (19)

Country Link
US (1) US5384124A (ja)
EP (1) EP0352190B1 (ja)
JP (1) JP2812723B2 (ja)
KR (1) KR0146960B1 (ja)
AT (1) ATE82118T1 (ja)
AU (1) AU626031B2 (ja)
CA (1) CA1340576C (ja)
DE (1) DE68903442T2 (ja)
DK (1) DK175095B1 (ja)
ES (1) ES2052947T3 (ja)
FI (1) FI97275C (ja)
FR (1) FR2634376B1 (ja)
GR (1) GR3006518T3 (ja)
IE (1) IE64907B1 (ja)
IL (1) IL91010A (ja)
NO (1) NO178526C (ja)
NZ (1) NZ230005A (ja)
PT (1) PT91237B (ja)
ZA (1) ZA895546B (ja)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649888B1 (fr) * 1989-07-18 1994-08-26 Exsymol Sa Produits pour applications cutanees, a effets cosmetiques ou/et therapeutiques
FR2657258A1 (fr) 1990-01-19 1991-07-26 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des particules sous forme de perles ainsi que sa preparation.
US5417985A (en) * 1989-07-20 1995-05-23 Farmalyoc Solid and porous single dosage form comprising particles in the form of beads and its preparation
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
FR2661610B1 (fr) * 1990-05-02 1994-09-30 Rhone Poulenc Sante Nouvelle forme lyophilisee de la diosmine et sa preparation.
US5458884A (en) * 1992-09-10 1995-10-17 Britton; Peter Bioerodible device for administering active ingredients
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
FR2720645B1 (fr) * 1994-06-03 1996-08-02 Oreal Procédé d'obtention d'une matière première sous forme de granulés, matière première sous forme de granulés et son utilisation dans le domaine cosmétique, capillaire, vétérinaire ou pharmaceutique.
EP0782850A4 (en) * 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
FR2726469B1 (fr) * 1994-11-08 1996-12-13 Adir Composition pharmaceutique pour l'administration orale de flavonoides
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US20010018417A1 (en) 1996-07-01 2001-08-30 Carson James W. Virginiamycin mixture
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
GB9802088D0 (en) * 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
EP1117384A1 (en) * 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
DE19931708A1 (de) 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−2阻害剤組成物
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
DE10008305A1 (de) * 2000-02-23 2001-09-06 Henkel Kgaa Mittel zur Reinigung und Pflege von Haut und/oder Haaren
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
ATE330633T1 (de) * 2000-07-27 2006-07-15 Pharmacia Corp Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
WO2002017877A2 (en) * 2000-08-31 2002-03-07 Universiteit Gent Controlled release pharmaceutical pellet compositions for reducing side effects of drugs
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20020131990A1 (en) * 2000-11-30 2002-09-19 Barkalow David G. Pullulan free edible film compositions and methods of making the same
TWI337083B (en) * 2001-01-26 2011-02-11 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
ES2266084T3 (es) * 2001-02-14 2007-03-01 Forte Iq B.V. Composicion farmaceutica que comprende una goma de xantano.
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
WO2002100381A1 (en) * 2001-06-07 2002-12-19 Tanabe Seiyaku Co., Ltd. Functional grain-containing preparations quickly disintegrated in the oral cavity
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
WO2003026662A1 (en) * 2001-09-25 2003-04-03 Pharmacia Corporation Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
GB0205253D0 (en) 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) * 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
WO2003105917A2 (en) * 2002-06-12 2003-12-24 Scimed Life Systems, Inc. Bulking agents
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
GB2399084B (en) 2002-07-30 2007-01-31 Univ Liverpool Porous beads and method of production thereof
US7842377B2 (en) 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US9023333B2 (en) 2002-10-16 2015-05-05 Stefan Frahling Method of using shaped articles to apply a scaffold-forming agent to an external skin and/or hair surface of a human or an animal
US7883490B2 (en) * 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
ES2365012T3 (es) * 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
KR100638104B1 (ko) * 2003-03-05 2006-10-25 학교법인 포항공과대학교 산화철 나노입자 함유 콜로이드 조성물의 제조방법
ES2318274T3 (es) * 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7976823B2 (en) * 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050123596A1 (en) * 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
US7901770B2 (en) * 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
DE102004007526A1 (de) * 2004-02-17 2005-09-01 Oetjen, Georg-Wilhelm, Dr. Verfahren und Einrichtung zur Gefriertrocknung von Produkten
US7736671B2 (en) * 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
US7311861B2 (en) * 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US8425550B2 (en) * 2004-12-01 2013-04-23 Boston Scientific Scimed, Inc. Embolic coils
US7858183B2 (en) * 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) * 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
US7963287B2 (en) * 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US20100003373A1 (en) * 2005-04-28 2010-01-07 Meiji Seika Kaisha, Ltd. Rapidly soluble granules and method for producing the same
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US8007509B2 (en) * 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
US20070083219A1 (en) * 2005-10-12 2007-04-12 Buiser Marcia S Embolic coil introducer sheath locking mechanisms
US20070142859A1 (en) * 2005-12-19 2007-06-21 Boston Scientific Scimed, Inc. Embolic coils
US8152839B2 (en) * 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US7947368B2 (en) * 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
EP1870649A1 (en) * 2006-06-20 2007-12-26 Octapharma AG Lyophilisation targetting defined residual moisture by limited desorption energy levels
US20070299461A1 (en) * 2006-06-21 2007-12-27 Boston Scientific Scimed, Inc. Embolic coils and related components, systems, and methods
EP1891938A1 (en) * 2006-07-24 2008-02-27 Cephalon France High dose orally dissolvable/disintegrable lyophilized dosage form
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
EP1905429A1 (en) * 2006-09-18 2008-04-02 Cephalon France Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US20080145658A1 (en) * 2006-12-15 2008-06-19 Boston Scientific Scimed, Inc. Freeze Thaw Methods For Making Polymer Particles
EP1980245A1 (en) * 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2211661A4 (en) * 2007-11-19 2015-01-07 Avon Prod Inc COMPOSITION AND METHOD FOR THE DRY APPLICATION OF MASCARA
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP2201939A1 (en) * 2008-12-25 2010-06-30 Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Method for producing coated spiramycin and novel formulations containing the same
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
TWI471127B (zh) 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
US20100323067A1 (en) * 2009-06-19 2010-12-23 Hershey Foods Corporation Temperature resistant chocolate composition and method
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
US20120288523A1 (en) 2010-01-04 2012-11-15 Antonius Arnoldus Christiaan Jacobs Administration route for a composition to protect an animal against rhodococcus equi
JP6166721B2 (ja) 2011-07-22 2017-07-19 ケモセントリックス, インコーポレイテッド 4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の多形
EP2748146B1 (en) 2011-07-22 2017-03-08 ChemoCentryx, Inc. A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
EP2751094B1 (en) 2011-09-01 2018-06-20 Glaxo Group Limited Novel crystal form
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
KR102493854B1 (ko) 2014-06-25 2023-01-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
EP3191480A1 (en) 2014-09-08 2017-07-19 GlaxoSmithKline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
US20200261266A1 (en) 2017-09-15 2020-08-20 Oxular Limited Ophthalmic Delivery Device
BR112022021040A2 (pt) 2020-04-16 2022-12-06 Tavanta Therapeutics Hungary Incorporated Métodos e composições para o tratamento de câncer de próstata

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1216349A (en) * 1966-12-21 1970-12-16 Luis Picas Tort A process for the manufacture of dispersible granulates
FR2004920A1 (en) * 1968-03-28 1969-12-05 Kyowa Hakko Kogyo Kk Antibiotic suppository formulation contng polyethylene glycol and carb - oxymethyl cellulose
DE1916884A1 (de) * 1969-04-02 1970-10-15 Vaillant Joh Kg Zuendbrenneranordnung
DE2017373A1 (de) * 1969-04-15 1971-04-22 Orsymonde S A , Paris Lyophihsierte Produkte und Ver fahren zu ihrer Herstellung
FR2036890B1 (ja) * 1969-04-15 1973-01-12 Orsymonde
IE45770B1 (en) 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4693912A (en) * 1985-02-28 1987-09-15 Technicon Instruments Corporation Lyophilization of reagent-coated particles
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
FR2581541B1 (fr) 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
ATE109659T1 (de) * 1986-03-21 1994-08-15 Eurasiam Lab Arzneimittelzusammensetzungen.
GB2192128A (en) * 1986-07-03 1988-01-06 Fa Ez Khan Production of pharmaceutical unit dosage forms
US4936901A (en) * 1986-07-09 1990-06-26 Monsanto Company Formulations of water-dispersible granules and process for preparation thereof
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
FR2613223B1 (fr) * 1987-04-03 1991-09-13 Biogalenique Laboratoires Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation

Also Published As

Publication number Publication date
IL91010A (en) 1993-03-15
FI97275B (fi) 1996-08-15
DE68903442T2 (de) 1993-05-06
NO178526B (no) 1996-01-08
CA1340576C (fr) 1999-06-01
US5384124A (en) 1995-01-24
NO178526C (no) 1996-04-17
IE892360L (en) 1990-01-21
FR2634376A1 (fr) 1990-01-26
NZ230005A (en) 1991-08-27
DE68903442D1 (de) 1992-12-17
ES2052947T3 (es) 1994-07-16
FI97275C (fi) 1996-11-25
FR2634376B1 (fr) 1992-04-17
PT91237B (pt) 1995-03-01
DK360489A (da) 1990-01-22
GR3006518T3 (ja) 1993-06-30
AU626031B2 (en) 1992-07-23
KR0146960B1 (ko) 1998-08-17
PT91237A (pt) 1990-02-08
DK175095B1 (da) 2004-06-01
EP0352190A1 (fr) 1990-01-24
JPH0288520A (ja) 1990-03-28
JP2812723B2 (ja) 1998-10-22
IL91010A0 (en) 1990-02-09
NO892985L (no) 1990-01-22
EP0352190B1 (fr) 1992-11-11
KR900001362A (ko) 1990-02-27
DK360489D0 (da) 1989-07-20
FI893504A0 (fi) 1989-07-20
AU3881989A (en) 1990-01-25
ATE82118T1 (de) 1992-11-15
FI893504A (fi) 1990-01-22
IE64907B1 (en) 1995-09-20
NO892985D0 (no) 1989-07-20

Similar Documents

Publication Publication Date Title
ZA895546B (en) New solid porous unitary form comprising micro-particles and/or nano-particles,and its preparation
IL84855A (en) Hydrosols of pharmacologically active agents,their preparation and pharmaceutical compositions containing them
GB2198042B (en) Cosmetic sunscreen composition for the face and body
MC1915A1 (fr) Procédés pour la préparation de 2',3'-didésoxynucléosides et de formulations pharmaceutiques en contenant
PT83556A (de) Biologisch aktive derivate des human-gama-interferons ihre herstellung und arzneimittel die solche derivate enthalten
GB2181053B (en) Pharmaceutical formulations with controlled release of the active substance
ZA888184B (en) New alkoxy derivatives of ginkgolides,their preparation and therapeutic compositions containing the same
IT8521528A0 (it) Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo.
FR2657258B1 (ja)
FR2612774B1 (fr) Compositions cosmetiques et pharmaceutiques, utilisees pour traiter le processus de l'alopecie androgenogenetique, contenant de l'acide azelaique
EP0052085A3 (en) Pharmaceutical composition containing vincamine
EP0410921A3 (en) Dressing for transcutaneous application of active substances for therapeutic or cosmetic purposes
FR2768627B1 (fr) Medicament veterinaire contenant de la choriogonadotropine equine modifiee pour induire l'ovulation chez la jument et stimuler la production de testosterone chez l'etalon
EP0275207A3 (en) Pharmaceutical, veterinary and cosmetic compositions and uses
PT85368B (en) 1,3-propanediamine derivatives preparation and pharmaceutical composition containing them
RU95100513A (ru) Паста для лечения кожных заболеваний
EP0464210A4 (en) Novel platinum complex and antitumor drug containing the same as active ingredient
ZA87500B (en) Symmetrical o-substituted dioximes of benzo-fused beta-diketocycloalkylenes,the processes for their preparation and their application as drugs
GR862457B (en) Pharmaceutical formulations with controlled release of the active substance
EP0417632A3 (en) 2-ethoxymethyl-5-hydroxy-gamma-pyrone and melanogenesis-inhibiting endermic preparation containing the same compound as active ingredient
GB2184656B (en) Cosmetic compositions for the treatment of greasy skin and hair.
GB2161706B (en) New pharmaceutical and cosmetic compositions containing 10-acetyl-1,8,9-triacetoxyanthracene as active ingredient
DE3573724D1 (en) Use of 1,8,9-triacetoxy-anthracene as the active ingredient in the preparation of an antitumoral pharmaceutical compound
AU1104888A (en) Cosmetic agent and composition for skin treatment
IT8619952A0 (it) Procedimento per la produzione di creme cosmetiche e medicinali.